JNJ-53718678 RSV Pre-Approval Access_Single Patient Access (SPR) for Patients Diagnosed With RSV
Latest Information Update: 30 Aug 2022
At a glance
- Drugs Rilematovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Expanded access
- Sponsors Janssen Sciences Ireland UC
- 11 May 2022 Status changed from recruiting to completed.
- 09 Jan 2020 New trial record